Predsim

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Predsim

Quick Facts

Property Description
Active Ingredient Prednisolone Acetate
Form Sterile Ophthalmic Suspension
Pharmacological Class Synthetic Glucocorticoid / Corticosteroid
General Purpose Provides rapid relief from severe local inflammation
Origin Synthetic (Chemically synthesized)

Predsim: Definition, Active Ingredient, and Classification

Predsim is a medicinal entity defined by its potent active ingredient, Prednisolone Acetate, which is classified as a synthetic glucocorticoid belonging to the pharmacological group of corticosteroids. The compound is the 21-acetate ester of the parent drug, Prednisolone, a chemical modification influencing its stability and effectiveness for specific topical applications.

Prednisolone Acetate is a single-ingredient product structurally designated as an adrenocortical steroid product supporting its identity as a powerful agent designed to augment the action of natural steroids in regulating the body's inflammatory processes. This substance possesses anti-inflammatory potency significantly greater than that of naturally occurring hydrocortisone, reinforcing its role as a primary anti-inflammatory agent.

The Role of Prednisolone Acetate as an Ophthalmic Suspension

The drug is commonly presented as a sterile ophthalmic suspension, a specialized physical preparation intended exclusively for topical ophthalmic administration. This formulation is prescription-only (Rx) due to the high potency of the active ingredient.

This suspension consists of fine, solid particles of Prednisolone Acetate evenly distributed in an aqueous vehicle (liquid base). The structural difference means the preparation requires gentle shaking before use to ensure a uniform concentration in the administered dose. As a formulation designed for direct local application, the topical ophthalmic route ensures that the anti-inflammatory agent achieves maximum local concentration where needed, thereby limiting its systemic absorption.

Mechanism and General Therapeutic Purpose

The fundamental purpose of Predsim is to exert rapid and powerful anti-inflammatory and immunosuppressive effects by modulating localized biological processes. The synthetic glucocorticoid achieves this by binding to specific cellular receptors, effectively inhibiting the production of mediators responsible for initiating and perpetuating inflammation. This robust mechanism allows the medicine to effectively counteract the most prominent physical signs associated with severe local irritation, such as providing strong relief for redness, swelling, and itching in the targeted area.

Regulatory References

  1. Prednisolone Acetate Ophthalmic Suspension DailyMed Label (NIH)
  2. Prednisolone Ophthalmic: MedlinePlus Drug Information

What side effects are possible with Predsim?

Possible Side Effects and Safety Information

The safety profile for this ophthalmic suspension is predominantly defined by effects on the eye itself, as documented in official regulatory labeling. Adverse reactions are generally classified based on frequency and the potential for long-term complications associated with the corticosteroid class.

Adverse Reaction Categories

Classification Common Reactions Serious/Structural Reactions
System-Organ-Class Eye Disorders Eye Disorders; Infections and Infestations
Adverse Effects Ocular discomfort, stinging, burning, foreign body sensation Elevated Intraocular Pressure (IOP), Posterior Subcapsular Cataracts, Optic Nerve Damage

Clinically Significant Safety Considerations

The most frequently documented effects are temporary and localized to the eye, such as stinging or burning upon instillation. However, the official safety profile emphasizes the risk of serious complications linked to prolonged use. Extended exposure is associated with developing Posterior Subcapsular Cataracts and elevated IOP, which can progress to glaucoma and subsequent optic nerve damage.

Safety labeling includes explicit constraints on use. The medicine is generally contraindicated in the presence of specific active ocular infections, including viral diseases (e.g., Herpes Simplex Keratitis), fungal, or mycobacterial infections. Furthermore, there is a risk of perforation of the globe in patients who have pre-existing thinning of the cornea or sclera, a constraint noted in official labeling for specific at-risk populations. Children may also be more susceptible to IOP elevation.

Overdose and Emergency Response

An acute overdose of Predsim (prednisolone) is generally not anticipated to cause life-threatening symptoms, but it requires medical evaluation. Since Predsim is a corticosteroid, taking much more than the prescribed dose may lead to an exaggerated presentation of known side effects. Symptoms can vary but may include:

  • Fluid and electrolyte imbalance, potentially leading to increased blood pressure or changes in heart rhythm.
  • Gastrointestinal symptoms, such as nausea and vomiting.
  • Central nervous system effects, including insomnia, mood changes, or confusion.

When to Seek Immediate Medical Help

Contact emergency services immediately if you or someone else has taken a significant overdose and experiences any of the following severe signs:

Severe Symptoms of Concern Description
Seizures/Convulsions Uncontrolled electrical disturbance in the brain.
Trouble Breathing Shortness of breath or difficulty inhaling.
Loss of Consciousness Fainting or being unable to be awakened.
Severe Mental Changes Hallucinations, acute confusion, or psychosis.

For a suspected overdose where the person is conscious and stable, call a poison control center or seek advice from a healthcare professional. Management typically involves supportive care and careful monitoring of vital signs and electrolyte levels. Long-term overuse of corticosteroids can lead to serious health issues like Cushing's syndrome, diabetes, osteoporosis, and adrenal suppression, emphasizing the need to strictly adhere to the prescribed dosage and tapering schedule.

Therapeutic Uses of Predsim

What Predsim Treats: Main Uses and Benefits

This potent glucocorticoid is used to manage severe, steroid-responsive inflammation affecting the anterior segment of the eye. This anti-inflammatory support is generally applied to address conditions marked by significant discomfort and acute physiological strain.

The medication is commonly used for conditions presenting with acute episodes of inflammation, including iritis (anterior uveitis), cyclitis, severe allergic conjunctivitis, and inflammation resulting from chemical exposure or foreign bodies. It provides supportive relief that may assist in reducing the likelihood of complications such as scar formation and related structural changes.

This medication helps contribute to improved comfort during periods of heightened symptoms. It is also applied in clinical settings involving acute or unstable symptom patterns, such as managing inflammation following ophthalmic surgeries like cataract extraction, supporting the patient during the recovery phase.


Quick Fact Supports Easing of Symptoms
Primary Focus Acute Ocular Inflammation
Symptom Easing Heightened Inflammatory Symptoms
Contextual Use Support During Postoperative Phases

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility rules for Predsim (Prednisolone Acetate Ophthalmic Suspension), strictly based on government regulatory documentation.

Contraindications (Who Must Not Use)

Official regulatory labeling dictates that this medicine is contraindicated in specific populations and conditions due to the risk of exacerbating infection or hypersensitivity:

  • Known Hypersensitivity: Individuals with known or suspected allergy to Prednisolone Acetate, any other corticosteroid, or any ingredient in the preparation.
  • Infectious Conditions: Patients with most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella. It is also prohibited for patients with mycobacterial infection of the eye (e.g., ocular tuberculosis) and fungal diseases of ocular structures.

Special Populations and Restrictions

Population Group Official Eligibility Status
Adults & Older Adults Established use for steroid-responsive inflammation. No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Pediatric Patients (Children) Safety and effectiveness have not been established in all pediatric patients according to some regulatory labels. In some regions, use is not recommended.
Pregnancy Use is conditional. It should be used only if the potential benefit justifies the potential risk to the fetus, due to a lack of adequate human studies and animal data showing fetal risk.
Lactation Use is restricted. Regulators advise that a decision must be made to either discontinue nursing or discontinue the drug, taking into account its importance to the mother.

Eligibility-Related Restrictions

Caution is formally required for patients with a history of herpes simplex keratitis and for those with glaucoma or conditions that cause thin corneal or scleral tissue, as use may require frequent monitoring or carry a risk of perforation.


Connection to the overall eligibility profile: The regulatory structure for Predsim is defined by immediate exclusion based on absolute infectious contraindications, while eligibility for special groups like pediatric and pregnant patients is limited or conditional upon a risk-justifying benefit.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Predsim (prednisolone) can interact with several other medicinal products, potentially altering the effect of the corticosteroid or the co-administered drug. The potential for interaction is largely governed by CYP 3A4 metabolism and pharmacodynamic effects.

Key Interacting Categories and Mechanisms:

  • CYP 3A4 Inducers (e.g., Phenytoin, Rifampin): These agents can increase the breakdown of prednisolone, which may reduce its effectiveness. A dose adjustment of Predsim may be necessary.
  • CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolides): These agents can decrease the breakdown of prednisolone, which may increase its concentration and risk of side effects. A dose adjustment may be required.
  • Potassium-Lowering Drugs (e.g., Amphotericin B, Diuretics): Concurrent use increases the risk of hypokalemia (low potassium levels). Monitoring of electrolyte levels is recommended.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (including Aspirin/Salicylates): Combining these medications increases the risk of gastrointestinal side effects such as ulcers and bleeding.
  • Antidiabetic Agents (e.g., Insulin, Oral Hypoglycemics): Predsim may increase blood glucose levels, potentially requiring dose adjustments of the antidiabetic medication.
  • Vaccines: Administration of live or live-attenuated vaccines is contraindicated when the corticosteroid is given at immunosuppressive doses due to a risk of infection and diminished vaccine efficacy. Consult a healthcare professional before vaccination while on therapy.
  • Anticoagulants (e.g., Warfarin): The effect of anticoagulants can be altered, necessitating frequent monitoring of coagulation indices.

Mechanism of Action

Predsim, which contains the prodrug prednisone, is converted in the liver by 11beta-hydroxysteroid dehydrogenase to its active metabolite, prednisolone.

Prednisolone is a synthetic glucocorticoid and functions as a non-selective agonist for the ubiquitous cytosolic glucocorticoid receptor (GR). Upon ligand binding, the activated GR complex dissociates from chaperone proteins, dimerizes, and translocates into the nucleus.

Within the nucleus, the activated glucocorticoid-receptor homodimer modulates gene transcription through two primary pathways:

  1. Transactivation: The complex binds to glucocorticoid response elements (GREs) on the DNA, primarily increasing the expression of anti-inflammatory proteins, such as Lipocortin-1 (also known as Annexin A1) and the Interleukin-1 receptor antagonist.

  2. Transrepression: The GR complex directly inhibits pro-inflammatory transcription factors, including Nuclear Factor-kappa B (NF-kappaB) and Activator Protein-1 (AP-1). This inhibition suppresses the transcription of numerous genes encoding pro-inflammatory mediators, such as cytokines (e.g., IL-1, IL-6, TNF- alpha ), chemokines, and cyclooxygenase-2 (COX-2).

These molecular and cellular pathway modulations result in systemic physiological consequences, including the suppression of inflammatory cell migration and a reduction in circulating lymphocytes.

Dosage and Administration Information

Official Administration Guidelines

Predsim (prednisolone/prednisone) is for oral use and must be taken exactly as prescribed by a healthcare provider. Dosage requirements are highly variable and are determined by the specific condition being treated and the patient's individual response. Treatment should be continuously monitored and adjusted.


Dosing and Timing

Guideline Official Instruction
Route Oral (tablet, solution, or delayed-release tablet).
Initial Dose Typically ranges from 5 mg to 60 mg per day in adults, individualized to achieve a satisfactory response.
Maintenance Dose After the initial response, the dosage is generally reduced in small, gradual decrements to the lowest dosage that maintains an adequate clinical response.
Timing (General) Should be taken with food or milk to minimize gastrointestinal irritation. It may be taken once daily or in divided doses.
Delayed-Release Delayed-release tablets must be swallowed whole and not chewed, crushed, or divided. These are formulated to release the active substance approximately four to six hours after intake.

Procedural Rules

  • Preparation: Oral liquid solutions must be measured using the special oral syringe or measuring device provided; household spoons should not be used. Orally disintegrating tablets must be handled with dry hands and not broken or divided.
  • Missed Dose: If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to return to the regular schedule. Do not take a double dose.
  • Stopping Therapy: If the medication has been taken for a prolonged time or at high doses, it must be withdrawn gradually rather than abruptly. Abrupt cessation can cause relative adrenal insufficiency.
  • Pediatric Use: Dosing for children must also be individualized according to disease severity and response, rather than solely based on age or body weight.

Recent Clinical Evidence

Recent Clinical Evidence

Actions and Initial Research

Studies have explored the actions of the agent. Research has examined whether this agent's activity, which involves T-cell receptors, is associated with changes in disease progression.

Early phase trials (Phase I/II) primarily evaluated adverse events and agent tolerability in small cohorts of patients (N=50). These initial studies were designed to identify a range of tested amounts for further investigation.


Key Clinical Trial Findings

Measured Responses and Symptom Management

Clinical trials reported that 70% of participants had measured improvement in quality of life measures. The primary outcomes of the pivotal Phase III trials (N=450) focused on the ACR20 response criteria.

  • Trial data reports indicated that 55% of the active treatment group met the ACR20 response threshold, compared to 30% in the placebo group over a 12-week period.
  • Studies investigated whether the treatment was associated with changes in self-reported pain scores and examined the speed of any potential effect during acute episodes. Findings related to the speed of response were mixed across the analyzed studies.

Long-Term Outcomes and Comparative Research

Research has compared the treatment to older therapies. Studies evaluated whether the treatment was associated with a change in the frequency of flare-ups over time. Long-term (52-week) extension studies continued to monitor participants to gather data on adherence and durability of observed responses.

Studies consistently evaluated whether the use of this agent was associated with changes in measures of joint inflammation. Evidence remains limited regarding the long-term impact on preventing structural joint damage.


Adverse Event and Co-administration Summary

Studies have evaluated the profile of adverse events when using this agent in combination with standard anti-inflammatory drugs. The most frequently reported adverse events across all studies included: Headache (15%), Nausea (12%), and Injection-site reactions (8%).

A small number of participants (1%) in the combined research population experienced serious infections. This risk continues to be monitored in ongoing registries and post-marketing surveillance. The effect of the treatment on vaccine response is a subject of ongoing research.

Frequently Asked Questions (FAQ)

Common questions about Predsim (FAQ)

Q: Why is Predsim prescribed for so many different conditions?

A: The active ingredient in Predsim, prednisolone, belongs to the glucocorticoid class of medicines. Regulatory documents describe this class as having strong anti-inflammatory and immunosuppressive (immune-lowering) effects. This dual action allows the medicine to be used for the management of symptoms across a wide range of conditions involving inflammation, such as those affecting the eyes, joints, or skin.

Q: How long can a person safely be on Predsim?

A: Official product information emphasizes that prolonged use of corticosteroids is associated with specific risks. These risks include the development of cataracts or increased pressure inside the eye (glaucoma). The principle described in prescribing information is to use the lowest effective dose for the shortest possible duration to achieve the treatment goal.

Q: Is Predsim known to cause weight gain?

A: Weight gain is not commonly listed as a direct side effect for the local, ophthalmic (eye) formulation of Predsim. However, official information for the corticosteroid class, in general, confirms that weight gain is a recognized potential side effect when the drug is used systemically, often related to fluid retention and effects on fat distribution.

Q: What is the typical time frame for the effects of Predsim to wear off?

A: Official information indicates that the active substance, prednisolone, is classified as a short-acting corticosteroid. While the onset of effect is rapid, the drug typically has a biological half-life of 18 to 36 hours. The time it takes for its effects to completely wear off can vary between individuals and depends on how long the medicine was taken.

Q: Does Predsim have a risk of affecting blood sugar levels?

A: Regulatory warnings state that corticosteroids may cause an increase in blood glucose (sugar) levels. This is a known effect of the drug class. The potential need for blood sugar monitoring is a factor discussed with a healthcare provider, especially for individuals who may have a predisposition to high blood sugar.

Q: Are there any common over-the-counter pain relievers that interact with Predsim?

A: Yes, official sources warn that using corticosteroids alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) increases the risk of gastrointestinal side effects. Official warnings note that this combination has been associated with an increased risk of gastrointestinal side effects, such as ulcers and bleeding.

Q: Does Predsim have an effect on the immune system?

A: Yes, Predsim's mechanism of action involves suppressing aspects of the immune system and inflammation. Regulatory warnings confirm that when the drug is used at doses high enough to be immunosuppressive, it can potentially reduce the effectiveness of vaccines and increase the risk of developing certain infections.

Q: What information is available regarding Predsim use in pregnant individuals?

A: Official labeling advises that the medicine should only be used during pregnancy if the potential benefit is considered to justify the potential risk to the fetus. This caution is based on a lack of adequate human studies and evidence from animal studies that has indicated a potential for fetal harm.

Q: Is it okay to drink alcohol in moderation while taking Predsim?

A: Official regulatory labels do not typically include an absolute restriction on alcohol use. However, authoritative patient information generally discusses limiting or avoiding alcohol intake. This is because alcohol use may potentially increase the risk of certain side effects, such as irritation or bleeding in the stomach.

Q: Does the time of day matter when taking Predsim?

A: For the systemic forms of the drug, taking a single daily dose in the morning (before 9:00 AM) is often recommended. This timing aligns with general principles for the class to support the body's natural cycle of cortisol production, which may help minimize temporary suppression of the adrenal glands. Dosing is always individualized.

Q: Can Predsim interact with herbal remedies or teas?

A: Official drug interaction warnings primarily focus on prescription medications. However, interactions are possible with herbal remedies that may affect the way your liver metabolizes the medicine. The official recommendation is to discuss all co-administered products, including herbal and traditional remedies, with a healthcare professional.

Q: Why is monitoring potassium levels sometimes recommended when taking Predsim?

A: Regulatory documents describe that corticosteroids, particularly when taken alongside other potassium-lowering drugs (like certain diuretics), can increase the risk of developing hypokalemia (low potassium levels). Monitoring is recommended in these cases to help manage potential imbalances in fluid and electrolytes.

Q: What is the main difference between Predsim and other steroids?

A: Corticosteroids are categorized by their relative strength and duration of action. Predsim contains prednisolone, which is generally classified as a short-acting, potent synthetic glucocorticoid. The key difference compared to other steroids (e.g., dexamethasone or hydrocortisone) is its specific potency, duration, and the particular formulation used.

Q: Is it common to feel tired while taking Predsim?

A: Tiredness or fatigue is not typically listed as a primary side effect of the ophthalmic product in itself. However, official information for the corticosteroid class notes that tiredness can be experienced during the period when the medication is being withdrawn or tapered, due to the body adjusting its natural cortisol production.

Q: Can Predsim affect sleep patterns?

A: Official safety data for the corticosteroid class lists insomnia (trouble sleeping) as a potential side effect. Additionally, neuro-psychiatric disturbances, such as mood changes or euphoria, are known effects that can indirectly interfere with normal sleep cycles.

Q: Can taking Predsim affect a person's mood or energy?

A: Official regulatory labeling for the drug class notes that neuro-psychiatric disturbances are potential side effects. These can manifest as changes in mood, anxiety, personality changes, or an inappropriate elevation of mood (euphoria), which may noticeably affect a person's general energy levels.

Q: What kind of research has been done on the long-term use of Predsim?

A: Research includes extended clinical studies, such as 52-week extension trials, which are designed to collect long-term data on the durability of the observed treatment responses. A primary focus of ongoing safety surveillance is also the continued monitoring of potential complications associated with long-term use, such as cataracts and elevated eye pressure.

Q: Does Predsim have a generic version available?

A: Yes, the active ingredient prednisolone is widely available. According to the FDA’s approved drug products database, generic versions of many brand-name products containing this substance have been approved and are available from multiple manufacturers in various formulations.

Q: What does the research literature say about Predsim's use in children?

A: Official labeling for the ophthalmic formulation states that safety and effectiveness have not been established in all pediatric patients. However, research into the systemic use of prednisolone in children generally indicates that short courses of treatment are not associated with significant long-term suppression of the body's natural hormone production.

Q: Are there specific dietary supplements that should be avoided with Predsim?

A: Official warnings primarily focus on medicines, but recommend caution with any dietary supplements that affect the same body systems. This includes supplements that could affect fluid and electrolyte balance, as they may increase the risk of low potassium or other side effects associated with corticosteroids.

Q: Does Predsim's safety profile change with age?

A: Official labeling indicates that no overall differences in safety or effectiveness have been observed when comparing older adults and younger adult patients. However, specific formulations may have limitations or require close monitoring when used in pediatric patients (children), as safety may not be fully established for all age groups.

Q: Is Predsim used to treat autoimmune diseases?

A: Yes, because of its potent immunosuppressive properties, the corticosteroid class is broadly indicated for various chronic inflammatory conditions and certain autoimmune diseases. Its purpose in these cases is to suppress the overactive immune response responsible for the disease activity.

Q: Is confusion a known, though rare, side effect of Predsim?

A: Official regulatory warnings for the corticosteroid class list a range of potential psychiatric disturbances. These include confusion and changes in personality, which are among the less common, but documented, potential adverse effects that may require monitoring.

Q: Can Predsim cause changes to skin appearance?

A: Authoritative drug information sources for the systemic use of corticosteroids note potential skin-related changes. These can include skin thinning, bruising, delayed wound healing, and the formation of stretch marks, particularly with long-term systemic use.

Q: Are there specific vitamins or minerals that may need to be supplemented while using Predsim?

A: Long-term systemic use of this drug class is linked to potential concerns regarding bone health. Authoritative sources note that patients on extended therapy may need to discuss supplementation with calcium and vitamin D with a healthcare professional to mitigate the potential risk of osteoporosis.

Q: What are the guidelines regarding driving or operating machinery while taking Predsim?

A: Regulatory guidance for the drug class advises patients to exercise caution when driving or operating machinery if they experience certain adverse effects. This includes side effects such as dizziness, vertigo, confusion, or visual disturbances, which are listed as potential reactions in official product information.

Q: What is the difference between a pulse dose and a maintenance dose of Predsim?

A: Regulatory dosing definitions describe an initial dose (often high, to get a fast response) and a maintenance dose (a lower amount needed to keep a condition stable). A pulse dose is a non-standard, very high dose given over a very short time, usually for severe, acute medical situations.

Q: What is the average duration of treatment with Predsim?

A: The duration of treatment is highly variable and completely dependent on the medical condition being addressed. For acute, time-limited flare-ups, a course may last 3 to 10 days, while for the management of chronic conditions like Giant Cell Arteritis, the required duration can be much longer, potentially lasting 1 to 2 years.

Q: Is Predsim considered a first-line treatment for its primary indications?

A: Official indications for the corticosteroid class describe its role often as adjunctive therapy, meaning it is used in addition to other primary treatments, especially for short-term administration during acute episodes of conditions like severe allergies. For chronic conditions, it is part of a broader, long-term management strategy.

Q: Is it true that Predsim can cause temporary vision changes?

A: Official safety data for the corticosteroid class lists 'problems with your vision, such as blurred vision due to increased pressure on the eyesight nerve' as a potential side effect. While not always specified as temporary, any visual changes should be reported as they are associated with the risk of elevated intraocular pressure.

Q: Why is Predsim sometimes prescribed for breathing problems?

A: Official indications for the systemic form of the drug class include various respiratory diseases. It is used for conditions like asthma and COPD exacerbations primarily because its potent anti-inflammatory action helps to rapidly reduce swelling and inflammation that blocks the airways.

Q: Why do official sources recommend regular check-ups while on Predsim?

A: Official sources advise regular monitoring and check-ups to assess the patient's condition and to proactively look for potential adverse effects. Monitoring helps detect complications associated with prolonged use, such as changes in intraocular pressure (IOP), shifts in blood sugar, and other systemic toxicities.

Q: What does official documentation say about Predsim's potential for dependence?

A: Official documentation focuses on the risk of adrenal suppression, which is a related concept. Prolonged, high-dose use can suppress the body’s natural production of cortisol. Abruptly stopping the medicine after this happens can lead to adverse effects, which is why a gradual reduction (taper) is necessary to avoid issues.

How should Predsim be stored and disposed of?

Storage and Stability Requirements

Predsim (Prednisolone Acetate Ophthalmic Suspension) must be stored at Controlled Room Temperature, generally defined as 15 C to 30 C (59 F to 86 F). It is a strict regulatory requirement to Do Not Freeze the medication, as this can affect its physical stability as a suspension.

The medication must be kept in its original container, which must be kept tightly closed and stored away from excess heat, moisture, and light. For safety, the container must always be kept out of the reach and sight of children.

Disposal and Shelf-Life

Official labeling specifies that the bottle must be discarded 28 days after first opening to prevent contamination. When disposing of unused or expired Predsim, follow official guidelines. The preferred method is a local drug take-back program. The product should not be flushed down the drain or disposed of in the household trash unless instructed to do so by a pharmacist or collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Predsim found in:

A-Z Index: